tirzepatide at the same time as hormone therapy Revolution: Is Dual Agonism The End Of Single-Pathway Therapy? GlobalRPH Tirzepatide plus hormone therapy increases

All GLP-1 receptor agonists and tirzepatide carry a boxed warning for risk of thyroid C-cell tumors and are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Phase 4: the 1.7mg acceleration dose (34 units) The jump from 1.0mg to 1.7mg is the largest single escalation in the standard protocol, a 0.7mg increase compared to the 0.25mg and 0.5mg jumps earlier

Mike Haney: I think that's a great place to wrap it up

The sequential nature of these steps MHRA authorisation, followed by NICE appraisal, followed by NHS commissioning means that routine NHS access to retatrutide, should it ultimately be approved, would follow a pathway similar to that of other recently authorised weight management medicines